Relay Therapeutics (NASDAQ:RLAY) Insider Sells $162,028.60 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Donald Bergstrom sold 8,660 shares of the stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $18.71, for a total value of $162,028.60. Following the completion of the transaction, the insider owned 409,897 shares in the company, valued at approximately $7,669,172.87. The trade was a 2.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Relay Therapeutics Stock Performance

Relay Therapeutics stock traded down $0.11 during mid-day trading on Wednesday, reaching $19.63. The stock had a trading volume of 4,272,836 shares, compared to its average volume of 3,411,490. The firm has a market capitalization of $3.76 billion, a PE ratio of -12.50 and a beta of 1.67. Relay Therapeutics, Inc. has a fifty-two week low of $3.03 and a fifty-two week high of $20.20. The stock’s 50-day simple moving average is $14.91 and its 200-day simple moving average is $11.72.

Relay Therapeutics (NASDAQ:RLAY) last issued its earnings results on Tuesday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The company had revenue of $3.00 million during the quarter, compared to the consensus estimate of $5.58 million. On average, research analysts forecast that Relay Therapeutics, Inc. will post -1.55 earnings per share for the current fiscal year.

Institutional Trading of Relay Therapeutics

Several institutional investors have recently made changes to their positions in the company. Sanctuary Advisors LLC raised its holdings in shares of Relay Therapeutics by 1.1% in the first quarter. Sanctuary Advisors LLC now owns 143,816 shares of the company’s stock valued at $1,431,000 after purchasing an additional 1,588 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Relay Therapeutics by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company’s stock worth $71,000 after purchasing an additional 1,757 shares in the last quarter. Abel Hall LLC increased its stake in Relay Therapeutics by 16.2% in the 4th quarter. Abel Hall LLC now owns 12,984 shares of the company’s stock valued at $110,000 after buying an additional 1,809 shares during the last quarter. Cresset Asset Management LLC lifted its position in shares of Relay Therapeutics by 5.0% during the 3rd quarter. Cresset Asset Management LLC now owns 38,932 shares of the company’s stock worth $203,000 after buying an additional 1,848 shares in the last quarter. Finally, Prelude Capital Management LLC lifted its position in shares of Relay Therapeutics by 18.7% during the 3rd quarter. Prelude Capital Management LLC now owns 19,700 shares of the company’s stock worth $103,000 after buying an additional 3,100 shares in the last quarter. Institutional investors own 96.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Citigroup reiterated an “outperform” rating on shares of Relay Therapeutics in a report on Wednesday, May 20th. Wall Street Zen raised shares of Relay Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. UBS Group set a $26.00 price target on Relay Therapeutics in a research note on Tuesday, May 19th. JonesTrading raised Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Finally, Barclays increased their price objective on Relay Therapeutics from $21.00 to $27.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $23.73.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.